

FORM PTO-1390 (Modified)  
(REV 10-95)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

## TRANSMITTAL LETTER TO THE UNITED STATES

99,849-A

DESIGNATED/ELECTED OFFICE (DO/EO/US)

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR

CONCERNING A FILING UNDER 35 U.S.C. 371

09/423698

INTERNATIONAL APPLICATION NO.

INTERNATIONAL FILING DATE

PRIORITY DATE CLAIMED

PCT/FR98/00966 ✓

14 May 1998 ✓

14 May 1998-1997

TITLE OF INVENTION

MULTIVALENT VACCINE COMPOSITION WITH MIXED CARRIER ✓

APPLICANT(S) FOR DO/EO/US

LEROY, Odile ✓

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371 (c) (2))
  - a. ☒ is transmitted herewith (required only if not transmitted by the International Bureau).
  - b. ☐ has been transmitted by the International Bureau.
  - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☒ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☒ A copy of the International Search Report (PCT/ISA/210).
8. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
  - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
  - b. ☐ have been transmitted by the International Bureau.
  - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
  - d. ☐ have not been made and will not be made.
9. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
10. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
11. ☒ A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).

## Items 13 to 18 below concern document(s) or information included:

13. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15. ☒ A **FIRST** preliminary amendment.  
A **SECOND** or **SUBSEQUENT** preliminary amendment.
16. ☐ A substitute specification.
17. ☐ A change of power of attorney and/or address letter.
18. ☒ Certificate of Mailing by Express Mail
19. ☐ Other items or information:

Express Mail Certificate; Return Postcard

**BASIC NATIONAL FEE ( 37 CFR 1.492 (a) (1) - (5) ) :**

**ENTER APPROPRIATE BASIC FEE AMOUNT =****CALCULATIONS** PTO USE ONLY

**\$970.00**

**\$130.00**

	\$54.00
--	---------

	\$0.00
--	--------

	<b>\$0.00</b>
--	---------------

**TOTAL OF ABOVE CALCULATIONS =**

	<b>\$1,154.00</b>
--	-------------------

\$0.00

**SUBTOTAL =**

	\$1,154.00
--	------------

\$0.00

**TOTAL NATIONAL FEE** =

	\$1,154.00
--	------------

\$0.00

**TOTAL FEES ENCLOSED**

**\$1,154.00**

Amount to be:	\$
---------------	----

<b>charged</b>	<b>\$</b>
----------------	-----------

☒ A check in the amount of **\$1,154.00** to cover the above fees is enclosed.

☐ Please charge my Deposit Account No. \_\_\_\_\_ in the amount of \_\_\_\_\_ to cover the above fees.  
A duplicate copy of this sheet is enclosed.

☒ The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Deposit Account No. **13-2490** A duplicate copy of this sheet is enclosed.

**NOTE:** Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

**SEND ALL CORRESPONDENCE TO:**

**Michael S. Greenfield**  
**Reg. No. 37,142**  
**McDonnell Boehnen Hulbert & Berghoff**  
**300 South Wacker Drive**  
**Chicago, Illinois 60606**  
**Phone: 312-913-0001**  
**Facsimile: 312-913-0002**

Michael J. Pythe  
SIGNATURE

**Michael S. Greenfield**

NAME \_\_\_\_\_

**37,142**

REGISTRATION NUMBER

**November 12, 1999**

DATE \_\_\_\_\_

09/423698

420 Rec'd PCT/PTO 12 NOV 1999

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
(Case No. 99,849-A)

In the Application of:	)	
	)	
Odile Leroy	)	Examiner: TBA
	)	
Serial No. U.S. National Phase of PCT/FR98/00966	)	Group Art Unit: TBA
	)	
Filed: November 12, 1999	)	
	)	
Title: Multivalent Vaccine Composition With mixed Carrier	)	

PRELIMINARY AMENDMENT

Asst. Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

Please consider the following amendments and remarks before calculation of the filing fee.

In the Claims:

4. (Amended) The [Composition] composition according to [Claim 1, 2 or 3,] Claim 1 in which "n" is a number equal to or greater than 6.
6. (Amended) The [Composition] composition according to [one of Claims 1 to 5,] Claim 1 in which the carrier proteins P1 to Pn are independently selected from a group consisting of two carrier proteins A1 and A2.
8. (Amended) The [Composition] composition according to [one of Claims 1 to 7,] Claim 1 in which at least one of the carrier proteins P1 to Pn is the diphtheria toxoid (Dt) and at least one of the carrier proteins P1 to Pn is the tetanus toxoid (Tt).

000120" 26522450

10. (Amended) The [Composition] composition according to [Claim 8 or 9,] Claim 8 in which the quantity of Dt is less than or equal to 200 µg/dose.

11. (Amended) The [Composition] composition according to [Claim 8, 9 or 10,] Claim 8 in which the quantity of Tt is less than or equal to 50µg/dose.

19. (Amended) The [Composition] composition according to [Claims 16, 17, or 18,] Claim 16 in which "n" is a number equal to or greater than 6.


21. (Amended) The [Composition] composition according to [one of Claims 16 to 20,] Claim 16 in which the polysaccharides S1 to Sn are of bacterial origin.

#### REMARKS

No new matter has been added to the application by way of these Amendments.

Respectfully submitted,

Date: November 12, 1999

By:   
Michael S. Greenfield  
Reg. No. 37,142

420 Rec'd PCT/PTO 12 NOV 1999

Multivalent vaccine composition with mixed carrier

The subject of the present invention is a pharmaceutical composition intended for the treatment or prevention of a number of infections caused by pathogenic agents such as bacteria, which comprises, as immunogenic agent, polysaccharides derived from one or more pathogenic agent.

Bacteria as well as fungi such as yeasts incorporate polysaccharides into their surface structure. Thus, the great majority of bacteria are coated with an exudate of a polysaccharide nature which is attached to the bacterium more or less firmly but which is strictly speaking not an envelope. This exudate is called glycocalyx or capsule. Moreover, the outer membrane of Gram-negative bacteria, consists, inter alia, of lipopolysaccharide (LPS). Finally, polysaccharides are also found in the wall of fungi. These polysaccharides are in fact surface antigens which induce an immune response in an infected mammal.

Such polysaccharides are produced on the basis of units in which the constituents and the bonds are defined and which are characteristic of the bacterial or fungal species considered. These repeating units contain the epitopes, that is to say the structures which determine antigenicity.

The polysaccharides of pathogenic micro-organisms are reputed to be good vaccine agents. As they are, they are effective in adults and children  
30 over two years. On the other hand, in breast-feeding infants, some are only slightly or not immunogenic and do not induce any immune response. It is possible to overcome this problem by coupling, via covalent bonding, the polysaccharides to a so-called carrier  
35 protein such as diphtheria or tetanus toxoid so as to obtain a polysaccharide-carrier protein conjugate.

The same vaccine composition may contain several conjugates. Indeed, the trend is to combine several vaccinal agents intended to prevent or to treat

[illegible]

infections induced by pathogenic agents from various species, this being, inter alia, in order to limit the number of administrations during the life of an individual. Furthermore, within the same species, there  
5 may be several serogroups/serotypes which are widely represented regionally or world-wide, It is this recalled that a serogroup/serotype is characterized, inter alia, by the nature of the capsule polysaccharide and that polysaccharides of various serogroups  
10 generally do not exhibit immunological cross-reactivity. In this case, it may therefore be necessary to combine the polysaccharides obtained from various serogroups in order to effectively combat an infection caused by one and the same species.

15 Thus, this is for example the case when it is sought to vaccinate against *Streptococcus pneumoniae* infections. Pneumococcal infections are a real public health problem especially since they are found in the severe forms of pneumonia, septicaemia and meningitis.  
20 In industrialized countries, they affect each year 30 to 100 per 100,000 children under three years. The mortality rate in cases of bacteraemia and meningitis is 15 to 30% whereas 5% of children die of pneumonia.

A study carried out in Finland from 1985 to  
25 1989 shows that 90% of invasive infections are caused by 8 groups of serogroups/serotypes. Serogroups/serotypes 14, 6 and 19 are responsible for 54% of cases, serotype 14 being predominant in children under two years. Other pneumococci frequently isolated belong  
30 to serogroups 7, 18 and 23; yet others, more rare, belong to serogroups/serotypes 9 and 4. A similar distribution has been demonstrated in other industrialized countries, in particular in the United States.

35 Moreover, *Streptococcus pneumoniae* is responsible for a number of otitis infections which are more benign but very common. The number of children that have had an otitis infection before the age of six is evaluated at about 75% and the number of otitis

000120 8692460

infections caused by pneumococcus at 30 to 50%. In developed countries, otitis infections caused by pneumococcus are due to serogroup 19 in 25% of cases, followed by serogroups/serotypes 23 (13%), 6 and 14 (12%), 9 and 18 (4%) and 4 and 1 (2%).

A pneumococcal vaccine containing the polysaccharides of 23 serotypes is already commercially available. This vaccine makes it possible to effectively combat invasive infections in adults and has a transient action in children over seven months.

The capsular polysaccharides of pneumococci are T-independent antigens, i.e. they can induce antibodies, preferably of the IgM type, without the help of T cells and are not capable of promoting a booster response of the IgG type. When they are coupled to a carrier protein, these polysaccharides then prove capable of inducing a T-dependent response, most particularly in neonates and should provide long-term protection.

Clinical studies have been carried out in Finland and Israel with pneumococcal vaccines having four valencies containing conjugates 6B, 9V, 18C and 23F in which the polysaccharide was coupled either to Dt or to Tt. The doses were 1, 3 or 10 µg of polysaccharide per valency. Each of these formulations was administered simultaneously with an anti-*Haemophilus* vaccine (polyribitolphosphate coupled to Tt; Act-HIB marketed by Pasteur Mérieux Connaught) and an anti-diphtheria, tetanus, whooping cough vaccine (for Finland, D.T.Coq marketed by KTL). Furthermore, these three administrations were carried out accompanied or not by simultaneous administration of an oral or injectable polio vaccine. They were repeated twice at a few weeks interval, and then once, one year after the first immunization.

The results of these studies as reported in the table below have made it possible to demonstrate an effect of negative interference of the diphtheria and

000720" 2692460

tetanus toxoid load on the induction of anti-HiB antibodies, after the last immunization.

Finnish study		Anti-HiB antibody in µg/ml
Placebo		11.00
Tetavalent pneumo		
Tt:	1 µg	10.1
	3 µg	7.18
	10 µg	4.11
Dt:	1 µg	11.5
	3 µg	12.5
	10 µg	7.18

Israeli study		Anti-HiB antibody in µg/ml
Placebo		6.62
Tetavalent pneumo		
Tt:	3 µg	2.81
Dt:	3 µg	4.62

5

A similar interference effect was observed during a clinical study in Iceland in which breast-feeding infants received Pro HIBit (PRP coupled to Dt; Connaught) in place of Act-HiB.

10

More generally, it is predicted that, regardless of the vaccine based on conjugated polysaccharides, a maximum load of Dt and of Tt or of any other protein exists in the conjugated vaccine or in the association or combination of vaccine administered above which the immune response against polysaccharides conjugated with this protein may be reduced. In order to overcome the problem which the phenomenon of negative interference constitutes in multivalent vaccines composed of polysaccharide conjugates, the present application proposes to use not one but at least two carrier proteins so that the maximum load of each of the carrier proteins is not reached.

15

20

000120" 869E2460

5

15

35

5 (ii) A composition containing at least three  
conjugates C1, C2, C3, ... Cn, of formulas S1-P1, S2-  
P2, S3-P3, ..... Sn-Pn, with: S1 to Sn all different  
from each other, P1 and P2 identical to each other, P3  
to Pn identical to each other and P1 and P2 different  
10 from P3 to Pn, and

Thus, for the purposes of the present invention, the conjugates C1 to Cn, which are necessarily all different from each other, may be so in pairs either through their polysaccharide, or through their carrier protein or through their polysaccharide and their carrier protein. According to a specific embodiment, the polysaccharides used are all different from each other.

The number "n" of conjugates present in a composition according to the invention is equal to or greater than 2, and may in particular be equal to or greater than 3, 4, 6, 8, 10, 11, 12, 15 or 20. In general, this number "n" may be determined by persons skilled in the art as a function of a number of criteria in particular linked to the very nature of the composition, to the objectives which this composition should make it possible to achieve and to the population for whom this composition is intended. For example, in the case of a composition intended for treating or preventing pneumococcal infections in breast-feeding infants, it is considered that such a composition, in order to offer a good level of

5           "Polysaccharide" is understood to mean a  
polymer consisting of a plurality of saccharide  
repeating units, especially of more than four repeating  
units, regardless of the length of the saccharide chain  
and regardless of the average molecular weight of the  
10 polysaccharide. This term covers in particular that of  
oligosaccharide.

15           Thus, as previously stated, a composition  
according to the invention should use at least two  
carrier proteins. These carrier proteins may be chosen  
from all those commonly used in the field of vaccines.  
They may be in particular the diphtheria toxoid (Dt),  
20 the tetanus toxoid (Tt), the non-toxic mutant form  
CRM197 of the diphtheria toxin and the outer membrane  
protein type 1 (OMP1) of *Neisseria meningitidis* or any  
variant, analogue or fragment of the latter which has  
preserved the carrier capacity. The methods which make  
25 it possible to obtain these proteins in purified form  
are well known to persons skilled in the art. The terms  
"protein" as used in the present application applies to  
any amino acid chain, regardless of the length of the  
chain. In particular, this term covers the notion of  
30 peptide.

In general, the group of proteins A1 to Am from which the carrier proteins P1 to Pn are independently selected therefore represents all the proteins having a carrier effect. For their personal needs, persons skilled in the art may agree that their choice would be limited to a defined number of proteins and, consequently, they can define the group which they will use to make their selection on the basis of a number "m" of components equal to or greater than 2 and at

most equal to "n", "n" being as defined above. In particular, persons skilled in the art can determine the minimum number of different carrier proteins which is necessary in order to avoid the phenomenon of interference. To do this, they will take into account the maximum load that should not be exceeded for each of the carrier proteins. "Maximum load" refers to the quantity of carrier protein above which a reduced immune response is observed against one or more polysaccharides compared with a corresponding monovalent composition (conjugate taken separately).

In particular, as regards the diphtheria toxoid and the tetanus toxoid, it is estimated that, advantageously, the quantity of these proteins present in a dose of a composition according to the invention should not exceed 200 and 50  $\mu$ g respectively, such a dose being envisaged for administration in a mammal, preferably a human. Preferably, the Dt load is less than or equal to 150, 120 or 100  $\mu$ g, most preferably 80 or 60  $\mu$ g. Preferably, the Tt load is less than or equal to 35 or 25  $\mu$ g, most preferably 20 or 10  $\mu$ g.

Thus, it may be accepted that for a composition using only two different carrier proteins, the selection of these proteins will be made from a group consisting of proteins A1 and A2. Preferably, A1 and A2 may be diphtheria toxoid (Dt) and tetanus toxoid (Tt) respectively or vice versa.

According to a specific embodiment, a composition using only two different carrier proteins is characterized by a balanced distribution of the number of polysaccharides conjugated with the first carrier protein and of the number of polysaccharides conjugated with the second carrier protein. For example, when "n" is an even number, "n"/2 carrier proteins P1 to Pn are A1 and "n"/2 carrier proteins P1 to Pn are A2 or when "n" is an odd number, ("n"+1)/2 carrier proteins P1 to Pn are A1 and ("n"-1)/2 carrier proteins P1 to Pn are A2.

0000720" 8692460

5

10

25

- 30

35

Under another aspect, a composition constituting a pneumococcal vaccine may comprise 10 or 11 valencies represented by 12 to 22, especially 12 to 15 conjugates, in which the polysaccharides are derived from the serotypes chosen from serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F, in which composition conjugates of the same valency differ from each other in the carrier protein. It may be in particular a composition which comprises:

- serotype 1 polysaccharide coupled to Tt;  
- serotype 3 polysaccharide coupled to Dt;  
- serotype 4 polysaccharide coupled to Tt;  
- serotype 5 polysaccharide coupled to Tt;  
15 - serotype 6B polysaccharide coupled to Dt;  
- serotype 6B polysaccharide coupled to Tt;  
- serotype 7F polysaccharide coupled to Tt;  
- serotype 9V polysaccharide coupled to Tt;  
- serotype 9V polysaccharide coupled to Dt;  
20 - serotype 14 polysaccharide coupled to Dt;  
- serotype 18C polysaccharide coupled to Dt;  
- serotype 18C polysaccharide coupled to Tt;  
- serotype 19F polysaccharide coupled to Tt;  
- serotype 23F polysaccharide coupled to Tt; and  
25 - serotype 23F polysaccharide coupled to Dt.

Such a polysaccharide may be advantageously extracted from the microorganism according to conventional methods and purified likewise. This polysaccharide may be used in the crude form after  
30 extraction/purification. Alternatively, it may be fragmented in order to obtain a polysaccharide having an average molecular weight less than that of the polysaccharide originally extracted. A particularly advantageous fermentation method is described in  
35 WO 93/7178 which is incorporated by way of reference.

A conjugate in which a polysaccharide is coupled by covalent bonding to a carrier protein may be obtained according to conventional methods well known to persons skilled in the art. It may make use of a

linker or a spacer to carry out the conjugation. Depending on the mode of conjugation used, the conjugate resulting therefrom may be a conjugate in which the polysaccharide is linked to the protein by a single chemical function (sun or neoglycoconjugate type), or by several functions (random coil type). It is within the capability of persons skilled in the art to determine the most appropriate mode of conjugation as a function of the nature of the polysaccharide and more particularly of the chemical groups carried by the polysaccharide which may be used during the conjugation reaction.

A composition according to the invention may be manufactured conventionally. In particular, it may be formulated with a pharmaceutically acceptable diluent or vehicle, e.g. water or a saline solution. In addition, the composition may contain customary ingredients such as a buffer, a preservative or stabilizer, an adjuvant such as an aluminum compound, e.g. an aluminium hydroxide, an aluminium phosphate or an aluminium hydroxyphosphate, and, where appropriate, a lyophilization excipient. In general, these products may be selected as a function of the mode and route of administration and based on standard pharmaceutical practices. Appropriate carriers or diluents as well as what is essential for the preparation of a pharmaceutical composition are described in *Remington's Pharmaceutical Sciences*, a standard reference book in this field.

A composition according to the invention may be administered by any conventional route which is used in the field of vaccines, in particular by the systemic, i.e. parenteral, route, e.g. by the subcutaneous, intramuscular, intradermal or intravenous route, or by the mucosal route, e.g. by the oral or nasal route.

The administration may take place in a single dose or in a dose repeated once or several times, e.g. once, twice or three times, after a certain interval of time. The appropriate dosage will vary as a function of

000120 8692460

5

10

15

20

25

30

35

5

a

10

[E]

Carrier protein	Polysaccharide	
	Serotype	Quantity per single dose
Dt	3	3 µg
Tt	4	1 µg
Dt	6B	10 µg
Tt	9V	1 µg
Dt	14	3 µg
Dt	18C	3 µg
Tt	19F	1 µg
Tt	23F	1 µg

20

EXAMPLE 2: Formulations F3, F4 and F3bis containing 11 valencies

Carrier Protein	Polysaccharide			
	Serogroup/ Serotype	Qty per single dose of formu- lation F3 (µg)	Qty per single dose of formu- lation F4 (µg)	Qty per single dose of formu- lation F3 bis (µg)
Tt	1	1	-	1
Dt	1	-	3	-
Dt	3	3	3	3
Tt	4	1	1	1
Tt	5	1	-	1
Dt	5	-	3	
Dt	6B	10	10	3
Tt	6B	-	-	1
Tt	7F	1	-	1
Dt	7F	-	3	-
Tt	9V	1	1	1
Dt	9V	-	-	3
Dt	14	3	3	3
Dt	18C	3	3	3
Tt	18C	-	-	1
Tt	19F	1	1	1
Tt	23F	1	1	1
Dt	23F	-	-	3

5           The approximate protein load in each of the three formulations is as follows:

	F3	F4	F3 bis
Dt	about 40 µg	about 60 µg	about 40 µg
Tt	about 15 µg	about 8 µg	about 18 µg

(which corresponds to a protein/polysaccharide weight  
10 ratio of about 2).

## Claims

1. Composition comprising "n" conjugates C1 to Cn, each conjugate being composed (i) of a polysaccharide derived from a *Streptococcus pneumoniae* serotype/serogroup S1 to Sn respectively, and (ii) of a carrier protein P1 to Pn respectively; "n" being a number equal to or greater than 2; in which composition the polysaccharides S1 to Sn are identical or different and in which the carrier proteins P1 to Pn are selected independently from a group consisting of "m" carrier proteins A1 to Am, "m" being a number equal to or greater than 2, provided that at least one of the carrier proteins P1 to Pn is different from the others.
2. Composition according to Claim 1, in which the conjugates C1 to Cn are all different from each other either by their polysaccharide or by their carrier protein or by their polysaccharide and their carrier protein.
3. Composition according to Claim 2, in which the polysaccharides S1 to Sn are all different from each other.
4. Composition according to Claim 1, 2 or 3, in which "n" is a number equal to or greater than 6.
5. Composition according to Claim 4, in which "n" is a number equal to or greater than 10.
6. Composition according to one of Claims 1 to 5, in which the carrier proteins P1 to Pn are independently selected from a group consisting of two carrier proteins A1 and A2.
7. Composition according to Claim 6, in which when "n" is an even number, "n"/2 carrier proteins P1 to Pn are A1 and "n"/2 carrier proteins P1 to Pn are A2 or when "n" is an odd number, ("n"+1)/2 carrier proteins P1 to Pn are A1 and ("n"-1)/2 carrier proteins P1 to Pn are A2.
8. Composition according to one of Claims 1 to 7, in which at least one of the carrier proteins P1 to Pn

is the diphtheria toxoid (Dt) and at least one of the carrier proteins P1 to Pn is the tetanus toxoid (Tt).

9. Composition according to Claim 8, in which the carrier proteins P1 to Pn are selected from the group consisting of Dt and Tt.

10. Composition according to Claim 8 or 9, in which the quantity of Dt is less than or equal to 200 µg/dose.

11. Composition according to Claim 8, 9 or 10, in which the quantity of Tt is less than or equal to 50 µg/dose.

12. Composition according to Claim 1, which comprises 10 or 11 valencies represented by 10 or 11 conjugates in which the polysaccharides are all different from each other and are derived from the serotypes chosen from serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F of *S. pneumoniae*.

13. Composition according to Claim 12, which comprises 10 or 11 conjugates selected from:

- serotype 1 polysaccharide coupled to Tt or to Dt;
- serotype 3 polysaccharide coupled to Dt;
- serotype 4 polysaccharide coupled to Tt;
- serotype 5 polysaccharide coupled to Tt or to Dt;
- serotype 6B polysaccharide coupled to Dt;
- serotype 7F polysaccharide coupled to Tt or to Dt;
- serotype 9V polysaccharide coupled to Tt;
- serotype 14 polysaccharide coupled to Dt;
- serotype 18C polysaccharide coupled to Dt;
- serotype 19F polysaccharide coupled to Tt; and
- serotype 23F polysaccharide coupled to Tt.

14. Composition according to Claim 1, which comprises 10 or 11 valencies represented by 12 to 22, especially 12 to 15 conjugates, in which the polysaccharides are derived from the serotypes chosen from serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F; in which composition conjugates of the same valency differ from each other in the carrier protein.

15. Composition according to Claim 14, which comprises:

- 35

20. Composition according to Claim 19, in which "n" is a number equal to or greater than 10.
21. Composition according to one of Claims 16 to 20, in which the polysaccharides S1 to Sn are of bacterial origin.
22. Composition according to Claim 21, in which the polysaccharides S1 to Sn are all derived from the same bacterial species.
23. Composition according to Claim 22, in which the polysaccharides S1 to Sn are all derived from the species *Streptococcus pneumoniae*.

000720" 859E2450

**DECLARATION AND POWER OF ATTORNEY  
• FOR PATENT APPLICATION**

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

**MULTIVALENT VACCINE COMPOSITION WITH MIXED CARRIER**

the specification of which is attached hereto unless the following space is checked:

☐ was filed on \_\_\_\_\_ as United States Application Serial Number \_\_\_\_\_.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT international application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s):

	<u>Number</u>	<u>Country</u>	<u>Day/Month/Year Filed</u>
1.	PCT/FR98/00966 ✓	PCT	05 May 1998 ✓
2.	97/06210	France	14 May 1997

I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States provisional application(s) listed below:

	<u>Application Number</u>	<u>Filing Date</u>
1.		
2.		

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s), or § 365(c) of any PCT international application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 C.F.R. § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

<u>Application Number</u>	<u>Filing Date</u>	<u>Status: patented, pending, abandoned</u>

I hereby appoint the following attorneys and agent(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

39-  
DENISE A. BERNTSEN  
JOHN J. McDONNELL  
DANIEL A. BOEHNEN  
BRADLEY J. HULBERT  
PAUL H. BERGHOFF  
GRANTLAND G. DRUTCHAS  
STEVEN J. SARUSSI  
DAVID M. FRISCHKORN  
JAMES C. GUMINA  
A. BLAIR HUGHES  
THOMAS A. FAIRHALL  
EMILY MIAO  
KEVIN E. NOONAN  
LEIF R. SIGMOND, JR.  
LAWRENCE H. AARONSON  
MATTHEW J. SAMPSON  
CURT J. WHITENACK  
CHRISTOPHER M. CAVAN  
MICHAEL S. GREENFIELD  
ROGER P. ZIMMERMAN

Reg. No. 26707  
Reg. No. 26949  
Reg. No. 28399  
Reg. No. 30130  
Reg. No. 30243  
Reg. No. 32565  
Reg. No. 32784  
Reg. No. 32833  
Reg. No. 32898  
Reg. No. 32901  
Reg. No. 34591  
Reg. No. 35285  
Reg. No. 35303  
Reg. No. 35680  
Reg. No. 35818  
Reg. No. 35999  
Reg. No. 36054  
Reg. No. 36475  
Reg. No. 37142  
Reg. No. 38670

ANTHOULA POMRENING (agent)  
GEORGE I. LEE  
JAMES M. MCCARTHY  
JEREMY NOE (agent)  
SEAN M. SULLIVAN  
AMIR N. PENN  
PATRICK J. HALLORAN (agent)  
JOSHUA R. RICH  
THOMAS E. WETTERMANN  
VERNON W. FRANCISSEN  
ROBERT J. IRVINE  
RICHARD A. MACHONKIN  
DAVID S. HARPER  
STEPHEN LESAVICH  
ENRIQUE PEREZ  
MARCUS J. THYMIAN  
S. RICHARD CARDEN (agent)  
MARK CHAEL (agent)  
STEPHEN H. DOCTER

Reg. No. 38805  
Reg. No. 39269  
Reg. No. 39296  
Reg. No. 40104  
Reg. No. 40191  
Reg. No. 40767  
Reg. No. 41053  
Reg. No. 41269  
Reg. No. 41523  
Reg. No. 41762  
Reg. No. 41865  
Reg. No. 41962  
Reg. No. 42636  
Reg. No. 43749  
Reg. No. 43853  
Reg. No. 43954  
Reg. No. 44588  
Reg. No. 44601  
Reg. No. 44659

Address all telephone calls to Michael S. Greenfield at (312) 913-0001.

Address all correspondence to MCDONNELL BOEHNEN HULBERT & BERGHOFF, 300 South Wacker Drive, Chicago, Illinois 60606 USA.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

1-00 Full name of first inventor: Odile Leroy

Inventor's signature: [Signature]

Residence: France

Citizenship: France

Post Office Address: 13, rue des Quatre Vents, F-92360 Garches FR

Date: 10/11/99